1. Sinatra ST, Roberts JC. Enhancing cardiac energy with ribose. Life Extension. 2007 May;13(50):26-31.
2. Gao L, Laude K, Cai H. Mitochondrial Pathophysiology, Reactive Oxygen Species, and Cardiovascular Diseases. Vet Clin North Am Small Anim Pract. 2008 Jan;38(1):137-55.
3. Kumar D, Lou H, Singal PK. Oxidative stress and apoptosis in heart dysfunction. Herz. 2002 Nov;27(7):662-8.
4. Sorescu D, Griendling KK. Reactive oxygen species, mitochondria, and NAD(P)H oxidases in the development and progression of heart failure. Congest Heart Fail. 2002 May;8(3):132-40.
5. Gustafsson AB, Gottlieb RA. Heart mitochondria: gates of life and death. Cardiovasc. 2008 Feb 1;77(2):334-43.
6. Zimmer HG, Ibel H. Ribose accelerates the repletion of the ATP pool during recovery from reversible ischemia of the rat myocardium. J Mol Cell Cardiol. 1984 Sep;16(9):863-6.
7. St Cyr JA, Bianco RW, Schneider JR, et al. Enhanced high energy phosphate recovery with ribose infusion after global myocardial ischemia in a canine model. J Surg Res. 1989 Feb;46(2):157-62.
8. Ward HB, Wang T, Einzig S, Bianco RW, Foker JE. Prevention of ATP catabolism during myocardial ischemia: a preliminary report. J Surg Res. 1983 Apr;34(4):292-7.
9. Wyatt DA, Ely SW, Lasley RD, et al. Purine-enriched asanguineous cardioplegia retards adenosine triphosphate degradation during ischemia and improves postischemic ventricular function. J Thorac Cardiovasc Surg. 1989 May;97(5):771-8.
10. Smolenski RT, Raisky O, Slominska EM, et al. Protection from reperfusion injury after cardiac transplantation by inhibition of adenosine metabolism and nucleotide precursor supply. Circulation. 2001 Sep 18;104(12 Suppl 1):I246-52.
11. Zimmer HG, Martius PA, Marschner G. Myocardial infarction in rats: effects of metabolic and pharmacologic interventions. Basic Res Cardiol. 1989 May;84(3):332-43.
12. Thirunavukkarasu M, Penumathsa S, Juhasz B, et al. Enhanced cardiovascular function and energy level by a novel chromium (III)-supplement. Biofactors. 2006;27(1-4):53-67.
13. Thirunavukkarasu M, Penumathsa SV, Juhasz B, et al. Niacin-bound chromium enhances myocardial protection from ischemia-reperfusion injury. Am J Physiol Heart Circ Physiol. 2006 Aug;291(2):H820-6.
14. Pauly DF, Pepine CJ. Ischemic heart disease: metabolic approaches to management. Clin Cardiol. 2004 Aug;27(8):439-41.
15. Pauly DF, Johnson C, St Cyr JA. The benefits of ribose in cardiovascular disease. Med Hypotheses. 2003 Feb;60(2):149-51.
16. Hegewald MG, Palac RT, Angello DA, Perlmutter NS, Wilson RA. Ribose infusion accelerates thallium redistribution with early imaging compared with late 24-hour imaging without ribose. J Am Coll Cardiol. 1991 Dec;18(7):1671-81.
17. Perlmutter NS, Wilson RA, Angello DA, et al. Ribose facilitates thallium-201 redistribution in patients with coronary artery disease. J Nucl Med. 1991 Feb;32(2):193-200.
18. Wallen WJ, Belanger MP, Wittnich C. Preischemic administration of ribose to delay the onset of irreversible ischemic injury and improve function: studies in normal and hypertrophied hearts. Can J Physiol Pharmacol. 2003 Jan;81(1):40-7.
19. Omran H, Illien S, MacCarter D, St CJ, Luderitz B. D-Ribose improves diastolic function and quality of life in congestive heart failure patients: a prospective feasibility study. Eur J Heart Fail. 2003 Oct;5(5):615-9.
20. Pliml W, von AT, Stablein A, et al. Effects of ribose on exercise-induced ischaemia in stable coronary artery disease. Lancet. 1992 Aug 29;340(8818):507-10.
21. Choo J, Burke LE, Pyo HK. Improved quality of life with cardiac rehabilitation for post-myocardial infarction patients in Korea. Eur J Cardiovasc Nurs. 2007 Sep;6(3):166-71.
22. Ades PA. Individualized preventive care in cardiac rehabilitation: adapted from AACVPR Award of Excellence Lecture, Charleston, WVa, October, 2006. J Cardiopulm Rehabil Prev. 2007 May;27(3):130-4.
23. Moore SM, Dolansky MA, Ruland CM, Pashkow FJ, Blackburn GG. Predictors of women’s exercise maintenance after cardiac rehabilitation. J Cardiopulm Rehabil. 2003 Jan;23(1):40-9.
24. Annesi J. Relations of self-motivation, perceived physical condition, and exercise-induced changes in revitalization and exhaustion with attendance in women initiating a moderate cardiovascular exercise regimen. Women Health. 2005;42(3):77-93.
25. Hellsten-Westing Y, Norman B, Balsom PD, Sjodin B. Decreased resting levels of adenine nucleotides in human skeletal muscle after high-intensity training. J Appl Physiol. 1993 May;74(5):2523-8.
26. Stathis CG, Febbraio MA, Carey MF, Snow RJ. Influence of sprint training on human skeletal muscle purine nucleotide metabolism. J Appl Physiol. 1994 Apr;76(4):1802-9.
27. Hellsten Y, Richter EA, Kiens B, Bangsbo J. AMP deamination and purine exchange in human skeletal muscle during and after intense exercise. J Physiol. 1999 Nov 1;520 Pt 3:909-20.
28. Tullson PC, John-Alder HB, Hood DA, Terjung RL. De novo synthesis of adenine nucleotides in different skeletal muscle fiber types. Am J Physiol. 1988 Sep;255(3 Pt 1):C271-7.
29. Zarzeczny R, Brault JJ, Abraham KA, Hancock CR, Terjung RL. Influence of ribose on adenine salvage after intense muscle contractions. J Appl Physiol. 2001 Oct;91(4):1775-81.
30. Tullson PC, Terjung RL. Adenine nucleotide synthesis in exercising and endurance-trained skeletal muscle. Am.J Physiol. 1991 Aug;261(2 Pt 1):C342-7.
31. Brault JJ, Terjung RL. Purine salvage to adenine nucleotides in different skeletal muscle fiber types. J Appl Physiol. 2001 Jul;91(1):231-8.
32. Hellsten Y, Skadhauge L, Bangsbo J. Effect of ribose supplementation on resynthesis of adenine nucleotides after intense intermittent training in humans. Am J Physiol Regul Integr Comp Physiol. 2004 Jan;286(1):R182-8.
33. Berardi JM, Ziegenfuss TN. Effects of ribose supplementation on repeated sprint performance in men. J Strength Cond Res. 2003 Feb;17(1):47-52.
34. Dunne L, Worley S, Macknin M. Ribose versus dextrose supplementation, association with rowing performance: a double-blind study. Clin J Sport Med. 2006 Jan;16(1):68-71.
35. Kerksick C, Rasmussen C, Bowden R, et al. Effects of ribose supplementation prior to and during intense exercise on anaerobic capacity and metabolic markers. Int J Sport Nutr Exerc Metab. 2005 Dec;15(6):653-64.
36. Op ‘t EB, Van LM, Brouns F, et al. No effects of oral ribose supplementation on repeated maximal exercise and de novo ATP resynthesis. J Appl Physiol. 2001 Nov;91(5):2275-81.
37. Peveler WW, Bishop PA, Whitehorn EJ. Effects of ribose as an ergogenic aid. J Strength Cond Res. 2006 Aug;20(3):519-22.
38. Segal S, Foley J, Wyngaarden JB. Hypoglycemic effect of D-ribose in man. Proc Soc Exp Biol Med. 1957 Jul;95(3):551-5.
39. Gross M, Reiter S, Zollner N. Metabolism of D-ribose administered continuously to healthy persons and to patients with myoadenylate deaminase deficiency. Klin Wochenschr. 1989 Dec 4;67(23):1205-13.
40. Dimroth P, von BC, Meier T. Catalytic and mechanical cycles in F-ATP synthases. Fourth in the Cycles Review Series. EMBO Rep. 2006 Mar;7(3):276-82.
41. Jain M, Cui L, Brenner DA, et al. Increased myocardial dysfunction after ischemia-reperfusion in mice lacking glucose-6-phosphate dehydrogenase. Circulation. 2004 Feb 24;109(7):898-903.
42. Pacher P, Szabo C. Role of poly(ADP-ribose) polymerase 1 (PARP-1) in cardiovascular diseases: the therapeutic potential of PARP inhibitors. Cardiovasc Drug Rev. 2007;25(3):235-60.
43. Zimmer HG. The oxidative pentose phosphate pathway in the heart: regulation, physiological significance, and clinical implications. Basic Res Cardiol. 1992 Jul;87(4):303-16.
44. Zimmer HG. Regulation of and intervention into the oxidative pentose phosphate pathway and adenine nucleotide metabolism in the heart. Mol Cell Biochem. 1996 Jul;160-161:101-9.
45. Clay MA, Stewart-Richardson P, Tasset DM, Williams JF. Chronic alcoholic cardiomyopathy. Protection of the isolated ischaemic working heart by ribose. Biochem Int. 1988 Nov;17(5):791-800.
46. Parang P, Singh B, Arora R. Metabolic modulators for chronic cardiac ischemia. J Cardiovasc Pharmacol Ther. 2005 Dec;10(4):217-23.
47. Pauly DF, Pepine CJ. D-Ribose as a supplement for cardiac energy metabolism. J Cardiovasc Pharmacol Ther. 2000 Oct;5(4):249-58.
48. Kendler BS. Supplemental conditionally essential nutrients in cardiovascular disease therapy. J Cardiovasc Nurs. 2006 Jan;21(1):9-16.
49. Lamberts RR, Caldenhoven E, Lansink M, et al. Preservation of diastolic function in monocrotaline-induced right ventricular hypertrophy in rats. Am J Physiol Heart Circ Physiol. 2007;293:H1869-H1876.
50. Teitelbaum JE, Johnson C, St CJ. The use of D-ribose in chronic fatigue syndrome and fibromyalgia: a pilot study. J Altern Complement Med. 2006;12:857-62. |